Form 13-F position report

POSEIDA THERAPEUTICS INC

Reported by Pentwater Capital Management LP

PSTX CUSIP 73730P108 Manager CIK 0001425851

Reported 0 shares, down 8,625,000 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q1 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 19 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 36211000
2021-12-31 33827000
2022-03-31 22253000
2022-06-30 12815000
2022-09-30 21092000
2022-12-31 31667500
2023-03-31 18403000
2023-06-30 10516000
2023-09-30 14220500
2023-12-31 20076000
2024-03-31 19060250
2024-06-30 17447000
2024-09-30 17088500
2024-12-31 82800000
2025-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for POSEIDA THERAPEUTICS INC held by Pentwater Capital Management LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2025 Reduced 0 -8,625,000 (-100.0%) 0 $0 2025-05-15
Q4 2024 Added 8,625,000 +2,650,000 (44.4%) 0.91% $82,800,000 2025-02-14
Q3 2024 Unchanged 5,975,000 0 (0.0%) 0.18% $17,088,500 2024-11-14
Q2 2024 Unchanged 5,975,000 0 (0.0%) 0.22% $17,447,000 2024-07-31
Q1 2024 Unchanged 5,975,000 0 (0.0%) 0.2% $19,060,250 2024-05-15
Q4 2023 Unchanged 5,975,000 0 (0.0%) 0.23% $20,076,000 2024-02-14
Q3 2023 Unchanged 5,975,000 0 (0.0%) 0.08% $14,220,500 2023-11-14
Q2 2023 Unchanged 5,975,000 0 (0.0%) 0.07% $10,516,000 2023-08-14
Q1 2023 Unchanged 5,975,000 0 (0.0%) 0.18% $18,403,000 2023-05-15
Q4 2022 Unchanged 5,975,000 0 (0.0%) 0.56% $31,667,500 2023-02-14
Q3 2022 Added 5,975,000 +1,007,773 (20.3%) 0.24% $21,092,000 2022-11-14
Q2 2022 Unchanged 4,967,227 0 (0.0%) 0.15% $12,815,000 2022-08-15
Q1 2022 Unchanged 4,967,227 0 (0.0%) 0.27% $22,253,000 2022-05-16
Q4 2021 Unchanged 4,967,227 0 (0.0%) 0.37% $33,827,000 2022-02-11
Q3 2021 Unchanged 4,967,227 0 (0.0%) 0.37% $36,211,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

116 managers reported POSEIDA THERAPEUTICS INC for Q1 2025.

Managers reporting POSEIDA THERAPEUTICS INC in Q1 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
DekaBank Deutsche Girozentrale Unchanged 100,000 0 < 0.01% $308,000 11 qtrs
IFP Advisors Inc Unchanged 0 0 < 0.01% $2 2 qtrs
Ameritas Investment Partners Inc Reduced 0 -7,182 0 $0 8 qtrs
Groupe la Francaise Reduced 0 -120,000 0 $0 1 qtr
SUSQUEHANNA INTERNATIONAL GROUP LLP Reduced 0 -198,375 0 $0 11 qtrs
NOMURA HOLDINGS INC Reduced 0 -5,115,015 0 $0 2 qtrs
FIFTH LANE CAPITAL LP Reduced 0 -50,100 0 $0 2 qtrs
MARSHALL WACE LLP Reduced 0 -146,232 0 $0 4 qtrs
CREDIT INDUSTRIEL ET COMMERCIAL Reduced 0 -80,000 0 $0 2 qtrs
Yakira Capital Management Inc Reduced 0 -177,404 0 $0 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
May 15, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.